abstract |
The present invention relates to humanized recombinant antibodies targeting EGFR family receptors EGFR, HER2 and HER3, comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody Antibody compositions, and uses of the antibody compositions for treating cancer. The present invention also relates to the use of antibodies targeting various EGFR family receptors to treat cancer, such as pancreatic cancer, and cancers that have acquired resistance to prior therapy. |